Create Account
Sign In
Dark
chart
exchange
Terminal
Screener
Stocks
Crypto
Forex
Watchlists
Trends

RDUS
Radius Health Inc.
stock NASDAQ

Inactive
8/12/2022
10.08USD-0.198%(-0.02)6,485,423
OverviewHistoricalExchange VolumeShort VolumeFailure to DeliverTrendsNewsMore
open chart   
Headquarters
Waltham, Massachusetts, USA
Industry
Drug Manufacturers
Related
AMGNBSTCNVSLLYCRLMRKALDRHZNPXLV
RDUS Stats
EPS (ttm)
-1.450
Jan 20, 2022
07:50AM EST  Radius Pharmaceuticals Filed U.S. Patent Application #20220016052 'METHODS FOR TREATING CANCER IN MODELS HARBORING ESR1 MUTATIONS'   Benzinga
Jan 13, 2022
11:48AM EST  Radius Health Says Fires ~20% Of Non-Sales Personnel   Benzinga
09:00AM EST  -- Completion of three pivotal trials in 2021 enables restructuring of the operating infrastructure -- Non-Sales headcount reduced by approximately 20% -- Reductions focused on areas that supported abaloparatide clinical and regulatory activities -- Company to provide Q4 & FY 2021 results and 2022 outlook during earnings on February 24   GlobeNewswire Inc
Dec 23, 2021
10:41AM EST  FDA Approves Update On Radius Health's Tymlos label   Benzinga
08:31AM EST  Radius Health Offers Update On TYMLOS Label: 'FDA approved the removal of the boxed warning from the TYMLOS label, effective December 22, 2021'   Benzinga
More News
Profile
Radius Health Inc. is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine and other therapeutics. Radius' lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases, initially targeting Prader-Willi syndrome.


Share
About
Symbol List

Pricing
Disclaimer

ChartExchange on Twitter
ChartExchange on Reddit
© 2020 - 2023 ChartExchange LLC